semaglutide cardiovascular outcomes news of and tirzepatide for patients with type 2 diabetes in clinical practice semaglutide cardiovascular outcomes news Population‐level

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as lowering the risks of heart and kidney problems.

Results from two late-stage clinical trials show that tripling the standard dose of semaglutide can significantly increase weight loss.

Leptin is a peptide hormone that plays a critical physiologic role in the human body, regulating appetite, food intake, and body weight by entering...

Convenient, transparent pricing with no insurance required

Learn about the GLP-1 receptor agonist injections for weight management, including injection areas, technique, safety tips, and doctor supervision at The Clifford Clinic.

This comparison is not as simple as 'tirzepatide wins, use tirzepatide.' The full picture is more nuanced.